872 related articles for article (PubMed ID: 30767742)
1. Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis.
Lu X
Curr Drug Targets; 2019; 20(10):1029-1040. PubMed ID: 30767742
[TBL] [Abstract][Full Text] [Related]
2. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
3. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
4. Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism.
Guo S; Xia XD; Gu HM; Zhang DW
Adv Exp Med Biol; 2020; 1276():137-156. PubMed ID: 32705598
[TBL] [Abstract][Full Text] [Related]
5. Role of PCSK9 in lipid metabolism and atherosclerosis.
Lin XL; Xiao LL; Tang ZH; Jiang ZS; Liu MH
Biomed Pharmacother; 2018 Aug; 104():36-44. PubMed ID: 29758414
[TBL] [Abstract][Full Text] [Related]
6. A transient amphipathic helix in the prodomain of PCSK9 facilitates binding to low-density lipoprotein particles.
Sarkar SK; Foo ACY; Matyas A; Asikhia I; Kosenko T; Goto NK; Vergara-Jaque A; Lagace TA
J Biol Chem; 2020 Feb; 295(8):2285-2298. PubMed ID: 31949048
[TBL] [Abstract][Full Text] [Related]
7. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
8. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
[TBL] [Abstract][Full Text] [Related]
9. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke.
Zhang L; Song K; Zhu M; Shi J; Zhang H; Xu L; Chen Y
Int J Neurosci; 2016 Aug; 126(8):675-80. PubMed ID: 26040332
[TBL] [Abstract][Full Text] [Related]
10. Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis.
Wu Y; Xu MJ; Cao Z; Yang C; Wang J; Wang B; Liu J; Wang Y; Xian X; Zhang F; Liu G; Chen X
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31779098
[TBL] [Abstract][Full Text] [Related]
11. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
[TBL] [Abstract][Full Text] [Related]
12. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.
Seidah NG; Prat A; Pirillo A; Catapano AL; Norata GD
Cardiovasc Res; 2019 Mar; 115(3):510-518. PubMed ID: 30629143
[TBL] [Abstract][Full Text] [Related]
13. [PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects].
Pedro-Botet J; Badimón L
Clin Investig Arterioscler; 2016 May; 28 Suppl 2():3-8. PubMed ID: 27888903
[TBL] [Abstract][Full Text] [Related]
14. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol.
Piper DE; Jackson S; Liu Q; Romanow WG; Shetterly S; Thibault ST; Shan B; Walker NP
Structure; 2007 May; 15(5):545-52. PubMed ID: 17502100
[TBL] [Abstract][Full Text] [Related]
15. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.
Ason B; van der Hoorn JW; Chan J; Lee E; Pieterman EJ; Nguyen KK; Di M; Shetterly S; Tang J; Yeh WC; Schwarz M; Jukema JW; Scott R; Wasserman SM; Princen HM; Jackson S
J Lipid Res; 2014 Nov; 55(11):2370-9. PubMed ID: 25258384
[TBL] [Abstract][Full Text] [Related]
16. PCSK9 Biology and Its Role in Atherothrombosis.
Barale C; Melchionda E; Morotti A; Russo I
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070931
[TBL] [Abstract][Full Text] [Related]
17. Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence.
Ferri N; Corsini A; Macchi C; Magni P; Ruscica M
Transl Res; 2016 Jul; 173():19-29. PubMed ID: 26548330
[TBL] [Abstract][Full Text] [Related]
18. PCSK9 and atherosclerosis: Looking beyond LDL regulation.
Ragusa R; Basta G; Neglia D; De Caterina R; Del Turco S; Caselli C
Eur J Clin Invest; 2021 Apr; 51(4):e13459. PubMed ID: 33236356
[TBL] [Abstract][Full Text] [Related]
19. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events.
Akin M; Skripuletz T; Napp LC; Berliner D; Akin I; Haghikia A; Akin E; Bauersachs J
Cardiovasc Hematol Agents Med Chem; 2017; 14(2):94-100. PubMed ID: 27470008
[TBL] [Abstract][Full Text] [Related]
20. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.
Schiele F; Park J; Redemann N; Luippold G; Nar H
J Mol Biol; 2014 Feb; 426(4):843-52. PubMed ID: 24252255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
